SYT (A7) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
SYT (A7) Peptide Applications :
Blocking Background :
The transcriptional coactivator SYT (synovial translocation protein) contains a conserved amino terminal SNH domain and a carboxy terminal QPGY domain, which is a functioning transcriptional activating sequence. Synovial sarcoma translocation (SSX) proteins, including SSX1–5, are transcriptional repressors that contain a repressor domain in their carboxy termini. SSX proteins are localized to the nucleus and expressed in testis and several types of cancers and, therefore, they are classified as C/T (cancer/testis) antigens. The t(x;18) translocation results in the fusion of the amino terminus of SYT to the carboxy terminus of either SSX1 or SSX2; both fusions result in the production of transcriptional activators. SYT-SSX chimeras are detected in most synovial sarcomas. Synovial sarcomas are responsible for up to 10% of soft issue sarcomas and are histologically characterized as either biphasic or monophasic.Genetic analysis indicates that biphasic synovial sarcomas contain SYT-SSX1 fusions, whereas SYT-SSX2 fusions are found in monophasic synovial sarcomas, providing additional distinguishing characterization of these subtypes. Alternative Name :
Protein SSXT; Protein SYT; Synovial sarcoma translocated to X chromosome protein; SS18; SSXT; SYT Swiss-Prot :
Q15532 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide SYT (A7). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS2069 SYT (A7) pAb.
SYT (A7) Peptide Applications :
Blocking Background :
The transcriptional coactivator SYT (synovial translocation protein) contains a conserved amino terminal SNH domain and a carboxy terminal QPGY domain, which is a functioning transcriptional activating sequence. Synovial sarcoma translocation (SSX) proteins, including SSX1–5, are transcriptional repressors that contain a repressor domain in their carboxy termini. SSX proteins are localized to the nucleus and expressed in testis and several types of cancers and, therefore, they are classified as C/T (cancer/testis) antigens. The t(x;18) translocation results in the fusion of the amino terminus of SYT to the carboxy terminus of either SSX1 or SSX2; both fusions result in the production of transcriptional activators. SYT-SSX chimeras are detected in most synovial sarcomas. Synovial sarcomas are responsible for up to 10% of soft issue sarcomas and are histologically characterized as either biphasic or monophasic.Genetic analysis indicates that biphasic synovial sarcomas contain SYT-SSX1 fusions, whereas SYT-SSX2 fusions are found in monophasic synovial sarcomas, providing additional distinguishing characterization of these subtypes. Alternative Name :
Protein SSXT; Protein SYT; Synovial sarcoma translocated to X chromosome protein; SS18; SSXT; SYT Swiss-Prot :
Q15532 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide SYT (A7). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS2069 SYT (A7) pAb.
Blocking peptide available as BS2069PP